Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePRNewsWire • 09/05/23
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 08/10/23
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The LancetPRNewsWire • 06/20/23
Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular RatePRNewsWire • 05/22/23
Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 05/11/23
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular RatePRNewsWire • 05/08/23
Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/12/23
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 03/29/23
Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVTPRNewsWire • 03/28/23
Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular TachycardiaPRNewsWire • 03/06/23
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 WeeksZacks Investment Research • 12/13/22
Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVTPRNewsWire • 11/29/22
Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare ConferencePRNewsWire • 11/22/22
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate UpdatePRNewsWire • 11/10/22
Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022PRNewsWire • 11/07/22
Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023Seeking Alpha • 11/05/22
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022PRNewsWire • 10/25/22
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 WeeksZacks Investment Research • 10/20/22
Milestone's (MIST) Tachycardia Study Data Fail to Impress InvestorsZacks Investment Research • 10/18/22
Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular TachycardiaPRNewsWire • 10/17/22